Author Year Country Study Design N Clinical Stage Neoadjuvant treatment Study Quality Response criteria Provided information on pathologic response poor response good response complete response Kim HJ [27] 2015 Korea retro 102 cII-IV CRT 8 ypTNM ypTNM II-IV ypTNM I and pCR NR Meng [26] 2014 Japan retro 314 cT2-4N0-2 CRT 9 pCR NR NR pCR Yeo [25] 2013 Korea retro 609 cT3-4N0-2M0, cII-III CRT 7 mTRGDworak TRG 1-2 TRG 3-4 NR Wang [20] 2013 China retro 240 cII-III RT 7 mTRG Bateman [49] >5% residual <5% residual pCR Lee [17] 2013 Korea retro 345 cT2-4N0-2M0 CRT 9 pCR NR NR pCR Restivo [18] 2013 Italy retro 260 cII-III CRT 9 pCR NR NR pCR Huh [16] 2013 Korea retro 391 cII-III CRT 9 pCR NR NR pCR Wallin [19] 2013 USA retro 469 cT1-4N0-2 CRT 8 pCR NR NR pCR Yan [24] 2011 China retro 98 cT3-4N-/N+ CRT 6 mTRGDworak TRG 0-2 TRG 3-4 NR Moureau [15] 2011 France retro 168 cT2-4N-/N+ CRT 8 pCR NR NR pCR Lin [21] 2010 China prospec-tive 47 cT3-4N-/N+ CRT 6 mTRGDworak TRG 0-2 TRG 3 TRG 4 Perez [14] 2009 Brazil retro 170 cI-III CRT 7 pCR NR NR pCR Yoon SM [13] 2007 Korea retro 351 cT3-4N-/N+ CRT 7 mTRGDworak TRG 1-2 TRG 3-4 TRG 4 Park [23] 2006 Korea retro 141 cT2-4N-/N+ CRT 7 Park[23] Remained patients only focal residual pCR

Table1: Characteristics of included studies.